

anticipated. Additional time was also included in the schedule for Tier II testing protocol development. Footnotes in Table 1. have been revised to address refinements in Tier II protocol development and extrapolation reporting changes identified as modification to Appendix C.5 (General

Outline for Route-to-Route Extrapolation Reporting) to correlate with Tier I study findings. Finally, one of the signatory companies to the ECA, Borden Chemicals and Plastics Operating Limited Partnership, is no longer a participant in the ECA, due to bankruptcy. The remaining companies

that are signatories of the ECA for TCE have agreed to assume the responsibilities for this change in membership to the HAP Task Force. EPA does not consider these modifications to be significant.

TABLE 1. (AMENDED)—REQUIRED TESTING, TEST STANDARDS, REPORTING AND OTHER REQUIREMENTS FOR 1,1,2-TRICHLOROETHANE

Testing Segment	Required Testing	Test Standard	Deadline for Final Report ¹ (Months)
Tier II Testing and/or Extrapolation Reporting	Acute neurotoxicity (drinking water)	§ 799.9620 (as annotated in ECA Appendix D.3)	12
	Acute neurotoxicity route-to-route extrapolation of Tier II drinking water acute neurotoxicity data to inhalation ²	ECA Appendix C	14
	Subchronic neurotoxicity (drinking water)	§ 799.9620 (as annotated in ECA Appendix D.3)	18
	Subchronic neurotoxicity route-to-route extrapolation of Tier II drinking water subchronic neurotoxicity data to inhalation ²	ECA Appendix C	21
	Developmental toxicity (drinking water)	§ 799.9370 (as annotated in ECA Appendix D.4)	24
	Developmental toxicity route-to-route extrapolation of Tier II drinking water developmental toxicity data to inhalation ³	ECA Appendix C	27
	Reproductive toxicity (drinking water)	§ 799.9380 (as annotated in ECA Appendix D.5)	30
	Reproductive toxicity route-to-route extrapolation of Tier II drinking water reproductive toxicity data to inhalation ⁴	ECA Appendix C	33
	Immunotoxicity (route-to-route extrapolation of extant oral data in ECA Appendix E.2 to inhalation) ⁵	ECA Appendix C	9
	Carcinogenicity (route-to-route extrapolation of extant oral data in ECA Appendix E.3 to inhalation) ⁶	ECA Appendix C	6

¹Number of months after the effective date of this **Federal Register** Notice, which announces that EPA has concluded the EPA Program Review, when the final report is due. In addition, every 6 months from the effective date of the Order until the end of the ECA testing program, interim reports describing the status of all testing to be performed under the ECA for TCE must be submitted by the companies to EPA.

²Quantitative route-to-route extrapolations based on the Tier II acute and subchronic drinking water neurotoxicity study data, and developed for each of the following dose metrics: Parent compound in venous blood and brain, as maximum concentration (C_{max}) and as the area under the time-concentration curve (AUC), and metabolite, as amount metabolized in the liver or brain per day normalized to organ weight.

³Quantitative route-to-route extrapolation based on the Tier II drinking water developmental toxicity study data, and developed for each of the following dose metrics: Parent compound in venous blood, as maximum concentration (C_{max}) and as the area under the time-concentration curve (AUC), and metabolite, as amount metabolized in the liver per day normalized to liver weight.

⁴Quantitative route-to-route extrapolation based on the Tier II drinking water reproductive effects toxicity study data, and developed for each of the following dose metrics: Parent compound in venous blood, as maximum concentration (C_{max}) and as the area under the time-concentration curve (AUC), and metabolite, as amount metabolized in the liver per day normalized to liver weight.

⁵Quantitative route-to-route extrapolation based on the PK/MECH data developed under this ECA and the data of Sanders et al. (1985), and developed for each of the following dose metrics: parent compound in venous blood and spleen, as maximum concentration (C_{max}) and as the area under the time-concentration curve (AUC), and metabolite, as amount metabolized in the liver or spleen per day normalized to organ weight.

⁶Quantitative route-to-route extrapolation based on the PK/MECH data developed under this ECA and the data of NCI (1978), and developed for each of the following dose metrics: parent compound in venous blood and liver, as maximum concentration (C_{max}) and as the area under the time-concentration curve (AUC), and metabolite, as amount metabolized in the liver per day normalized to liver weight.